Westcot Ventures Corp. Announces Closing of Transaction of WPD Pharmaceuticals Sp. Z.o.o.

Westcot Ventures Corp. (the "Company" or "Westcot") is pleased to announce that it has completed its acquisition (the "Transaction") of 100% of the issued and outstanding securities of WPD Pharmaceuticals Sp. Z.o.o. ("WPD") pursuant to a share exchange agreement dated July 17, 2019, as amended on November 25, 2019, among the Company, WPD and the securityholders of WPD (the "WPD Securityholders").

Pursuant to the completion of the Transaction, the Company issued 67,000,000 common shares to the WPD Securityholders in exchange for 100% of the issued and outstanding securities of WPD. Upon completion of the Transaction, WPD has become a wholly-owned subsidiary of the Company and the Company intends to continue the business of WPD.

Upon completion of the Transaction, there are an aggregate of 111,520,388 common shares of the Company issued and outstanding, of which the prior shareholders of the Company hold approximately 37.4% in the capital of the Company, and the former WPD Securityholders hold approximately 62.6% in the capital of the Company.

Prior to the completion of the Transaction, and as previously announced, the Canadian Securities Exchange (the "CSE") conditionally approved the listing (the "Listing") of the Company's common shares (the "Shares") and the Company completed its voluntary delisting from the NEX Board of the TSX Venture Exchange effective as of the close of business on December 18, 2019.

Listing of the Shares is subject to, among other things, satisfaction of the customary listing conditions of the CSE. Subject to satisfaction of these and other conditions, the Company anticipates that the Shares will begin trading on the CSE under the trading symbol "WBIO".

A listing statement describing the Company and its new business, prepared in accordance with the policies of the CSE, will be made available on the CSE's website and on SEDAR at www.sedar.com. The information regarding the Company and the Transaction in this press release is qualified in its entirety by reference to the more detailed disclosure included in the listing statement.

Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,
for any copyright disputes involved in the reproduced articles,
please email: Julia.Zhang@ubmsinoexpo.com to motify or remove the content.